A Study to Evaluate the Effect of Famciclovir in Reducing Herpes Virus Shedding

A Study to Evaluate the Effect of Famciclovir in Reducing Herpes Virus Shedding

The study is designed to assess the efficacy and safety of famciclovir 250 mg twice a day (bid) suppressive treatment in men and women with herpes virus type 2 (HSV-2) infection, with and without a reported history of genital herpes and with or without herpes virus type 1 (HSV-1) seropositivity.

Inclusion Criteria:

• Males or non-pregnant females at least 18 years of age with HSV-2 seropositive serology with or without history of clinically diagnosed recurrent genital herpes

Exclusion Criteria:

• Pregnancy
• History of renal dysfunction
• Use of immunosuppressive therapy, including steroids (other than topical or inhaled), or use of probenecid
• Hypersensitivity to famciclovir, valacyclovir or drugs with similar chemical structure